chartexchange

Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire Inc. | Nov 16, 2026 4:05 PM EST

– Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –

Read original article